FORDYCE MARSHALL (President and CEO) sold 8.9% of their position (22.95K shares) of VERA THERAPEUTICS, INC. on the open market
Open‑market sale worth $1.01M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 4/15/2026ACC: 0001859453-26-000006
DirectorOfficer· President and CEO
Since May 2021
-22.95K
Net shares
Net seller
$1.01M
Total sold
3
Open market trades
0B · 3S
3
Total transactions
22.95K disposed
Non-Derivative Transactions3
Class A Common Stock
Direct
Shares
−14.13K
Price / share
$43.66
Trade value
$616.99K
% of position
5.5%
4/14/2026
258.19K→244.06K
Class A Common Stock
Direct
Shares
−7.92K
Price / share
$44.58
Trade value
$353.11K
% of position
3.2%
4/14/2026
244.06K→236.14K
Class A Common Stock
Direct
Shares
−900.00
Price / share
$45.51
Trade value
$40.96K
% of position
0.4%
4/14/2026
236.14K→235.24K
Total
Net shares
−22.95K
Net value
-$1.01M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 4/14/2026 | S · Sale | −14.13K | $43.66 | $616.99K | 5.5% | 258.19K | 244.06K |
| Class A Common Stock Direct | 4/14/2026 | S · Sale | −7.92K | $44.58 | $353.11K | 3.2% | 244.06K | 236.14K |
| Class A Common Stock Direct | 4/14/2026 | S · Sale | −900.00 | $45.51 | $40.96K | 0.4% | 236.14K | 235.24K |
| Total | −22.95K | -$1.01M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Class A Common Stock
IndirectShares owned122.95K
Class A Common Stock
IndirectShares owned99.08K
Total
222.03K indirect222.03K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Common Stock | 122.95K | Indirect |
| Class A Common Stock | 99.08K | Indirect |
| Total | 222.03K | 222.03K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported